BACKGROUND: Alemtuzumab has recently been approved for treatment of relapsing @entity15 , but concerns remain about its use since long-term studies of adverse events remain limited. Furthermore, a clear understanding of its application and durability of effect in clinical practice has yet to evolve. OBJECTIVES: To investigate long-term efficacy and safety outcomes in a multicentre cohort of @entity1 treated with alemtuzumab. METHODS: @entity1 treated from 2000 and followed-up at three regional centres were identified. Baseline and prospective data were obtained and validated by clinical record review. RESULTS: One hundred @entity1 were identified with a mean follow-up of 6.1 years (range 1-13). Forty @entity1 were retreated with at least one further treatment cycle. Annualized relapse rates fell from 2.1 to 0.2 (p<0.0001) post-treatment and were sustained for up to eight years of follow-up. Mean change in EDSS score was +0.14. Forty-seven @entity1 developed secondary autoimmunity. CONCLUSION: Observed reduction in relapse rates reflected those reported in clinical trials, but we were unable to corroborate previous observations of disability reversal. 40% of @entity1 required additional treatment cycles. Autoimmune adverse events were common, occurring at a higher rate than previously reported, but were largely predictable, and could be managed effectively within a rigorous monitoring regime.

Alemtuzumab for XXXX : Long term follow-up in a multi-centre cohort.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity15 :: ('MESH:D009103', 'Disease') :: ['MS']
@entity15 :: (MESH:D009103,Disease) :: ['multiple sclerosis']
